Skip to content

ViralLoop

Your next post already worked.

←

Write from this board Add posts Share

AllXLinkedInInstagramTikTok

FilterOrderGridTableSelect

Loading the board

Viatris — how they publish · ViralLoop

Viatris — how they publish

Remix this board

10 posts · curated by ViralLoop

80 posts from @ViatrisInc, Sep 2024 to Sep 2026: a typical post earns 6 likes and 1 reply. That is more than 50% of the 275 other S&P 500 companies we hold content for. About 1 in 3 of their posts announces something. Posts with an image or video earn a median of 7 likes (72 posts); text alone 3 likes (8).

AllX LinkedIn Instagram TikTok

Viatris@ViatrisInc

$VTRS reports strong financial results for the fourth quarter and full year 2024. Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to fwd-looking statements. t.co

Opens with an observation

18 likes5 repliesIn reviewGeneralX1y ago

Viatris@ViatrisInc

Today we announced the filing of supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare (MHLW) for the approval of EFFEXOR® for the treatment of Generalized Anxiety Disorder (GAD). Read for more information here: t.co

Opens with an announcement

15 likes0 repliesIn reviewGeneralX1y ago

Viatris@ViatrisInc

Today we announced the FDA approval of the first generic iron replacement product to treat iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD),helping facilitate increased access to this complex injectable product. Information here: t.co

Opens with an announcement

14 likes3 repliesIn reviewProductX1y ago

Viatris@ViatrisInc

We are celebrating a big win by #TeamCongress at last week’s @CWSoftballGame! In addition to bringing together bipartisan lawmakers and members of the press corps, this game supports @YSCBuzz in its mission to address the unique needs of young adults affected by breast cancer.

Opens with an observation

13 likes0 repliesIn reviewGeneralX1y ago

Viatris@ViatrisInc

$VTRS reports first quarter 2025 results and reaffirms 2025 outlook. Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to fwd-looking statements. t.co

Opens with a number

13 likes1 repliesIn reviewGeneralX1y ago

Viatris@ViatrisInc

Today we announced that the US FDA has accepted our sNDA for an investigational treatment for presbyopia, an age-related progressive loss of the ability to focus on close objects that results in blurred near vision and eye strain. More information: t.co

Opens with an announcement

12 likes0 repliesIn reviewGeneralX6mo ago

Viatris@ViatrisInc

🏃Our team in Romania covered over 650 kilometers in support of Ajungem MARI, with each step contributing to funding education for abandoned children. Thank you to everyone who ran, cheered, and supported!

Opens with a number

12 likes4 repliesIn reviewHiringX1y ago

Viatris@ViatrisInc

We are here in Madrid at the #ESCCongress. Visit us at booth A200 to learn more about our efforts in reducing the burden of cardiovascular diseases and the latest on the SOS-AMI trial. #ESCCongress #WCCardio

Opens with an observation

11 likes1 repliesIn reviewScienceX1y ago

Viatris@ViatrisInc

Today we announced that five abstracts from our Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in moderate-to-severe acute surgical pain models will be presented at the PAINWeek 2025 national conference. Learn more: t.co

Text on violet background that reads "Data on novel fast-acting Meloxicam (MR-107A-02) to be presented at PAINWeek 2025 Conference

Opens with an announcement

11 likes1 repliesIn reviewAIX1y ago

Viatris@ViatrisInc

Today we announced positive top-line results from our second pivotal Phase 3 VEGA-3 Trial in presbyopia. Read for more information here: t.co

Opens with an announcement

11 likes2 repliesIn reviewScienceX1y ago

Boards are how ViralLoop learns your taste — save posts you admire, and turn the collection into content that sounds like you.

Start your own board